Members of the CADDA Advisory Board and CADDA Management Team at the 2025 CKTV Application Reviews
Our Advisory Board provide independent specialist sector knowledge, expertise and advice to the Management Team to help in the execution and development of the CADDA programme. To ensure a range of perspectives, they come from a variety of backgrounds, from academia to industry and with a wealth of experience, in the development of diagnostics, in medtech, therapeutics, AI, and including the patient voice.
As an Advisory Board their focus is on challenging and supporting CADDA on delivery and ensuring alignment and strategic direction with wider diagnostic needs, priorities and industry strengths, to provide the best possible project outcomes.
Garry Rogerson, Chair
Dr. Rogerson is a seasoned leader in scientific and industrial technologies. He served as Chairman and CEO of Varian Inc. until its acquisition by Agilent Technologies in 2010, following senior roles including COO and SVP of Scientific Instruments. He was Chairman of Coherent Inc. for 15 years, guiding growth in laser and optics technologies, and later CEO and Board Member of Advanced Energy Industries until 2015. Since then, he has focused on private investing.
Holding a PhD in Biochemistry and an honorary science doctorate from the University of Kent, Dr. Rogerson brings deep expertise in diagnostics development, start-ups, and strategic leadership across the sector.
Andrew Osman
Andrew is a Senior Healthcare Strategy Consultant at Roche Diagnostics and co-leads Roche Healthcare Consulting’s Global Strategic Consulting Community of Practice. He has extensive experience driving healthcare transformation both across the UK and internationally. He develops and leads strategic programmes focused on change management, implementation science, improvement science and value-based healthcare, enabling real world adoption of innovation through pathway redesign and organisational transformation. With a background in marketing, consulting and entrepreneurship, Andrew brings expertise in strategy development, clinical pathways, and building strategic partnerships to deliver sustainable healthcare solutions.
Nicola Clear
Previously a Director of Pharmaceutical Sciences for Pfizer, Nicola now consults for a range of organisations as a pharmaceutical sciences leader and digital transformation strategist in pharma and biotech R&D, especially in AI, predictive modelling and intelligent workflows. She is Director of Cepheus Consultancy, Strategic Advisor Life Sciences for i2e Consulting and Strategic Business Development consultant for NGT BioPharma Consultants. She brings over 30 years of experience in the global pharmaceutical industry, spanning drug and drug–device development, from molecule selection in Discovery, through formulation and clinical development, to ensuring therapeutics and delivery devices meet commercial and patient needs. She helps life sciences clients streamline decision-making through data-driven insights, personalized solutions and change management frameworks that simplify processes, particularly in resource management and workforce planning.
Robert Field
Professor Field is an internationally recognized leader in carbohydrate chemistry and biochemistry, and co-founder and CEO of Iceni Glycoscience, developing carbohydrate-based diagnostics, vaccines, and therapeutics. He is Pro Vice Chancellor for Science at UEA and recently serves as President of the Chemistry-Biology Interface Division of the Royal Society of Chemistry. His research explores how carbohydrates influence biological processes, with applications in medicine, nutrition, and industrial biotechnology, addressing challenges from infectious diseases to sustainable nutrition. Previously, he directed the Manchester Institute of Biotechnology and was a group leader at the John Innes Centre.
Nick Major
Dr. Major retired after 34 years with Genzyme/Sekisui Diagnostics, including 16 years as Director of R&D, leading protein expression, purification, and IVD development. At Sekisui, he was one of the leaders in strategy for enzymes in Diagnostics and CDMO partnerships in biopharma and diagnostics. Today, he serves on the advisory board of the SoCoBio Doctoral Training Programme and mentors for the Kent Refugee Action Network. His expertise spans fermentation, protein purification, process validation, technical transfer, and strategic collaboration, alongside extensive leadership experience in quality, business modeling, and team development.
Emily Adams
Dr. Adams is Chief Global Health Officer at Global Access Diagnostics, leading efforts to improve equitable access to diagnostics worldwide and strengthen pandemic preparedness. She is Associate Professor of Translational Diagnostics at the Pandemic Sciences Institute, University of Oxford, and formerly Reader in Infectious Disease Diagnostics at the Liverpool School of Tropical Medicine. Her work spans the development and evaluation of diagnostics for diseases such as malaria, pandemic disease inc SARS-CoV-2, and trypanosomiasis. She has consulted for WHO-TDR, FIND, and the Gates Foundation, with research funded by MRC, Wellcome Trust, and FCDO.
Malcolm Rhodes
Dr. Rhodes acts in a Public and Patient role on the Advisory Board. He has a wealth of knowledge and experience in bioprocessing, biologics manufacturing, portfolio management and product development. He formerly consulted in biopharmaceuticals and was a fellow at the University of Manchester for 6 years. Malcolm has awide range of experience in R&D and senior management roles at Pfizer Ltd, Celltech Ltd, Bioscot Ltd., Serologicals and in Healthtech and Medicines KTN. He currently acts as aPatient Advocate for charities and lymphoma researchers.
Aileen McGettrick
Dr. McGettrick is an experienced IVD specialist in point-of-care diagnostics with 20 years in assay development. She co-founded Psyros in 2018 to develop ultra-sensitive diagnostics, later acquired by Prolight Diagnostics, where she serves as Board Member and Chief Scientific Officer. Aileen holds a PhD in biochemistry and genetics from Oxford and completed postdoctoral research at Oxford and Harvard-affiliated Joslin Diabetes Center. Previously, she led assay development teams at Vivacta and Novartis, focusing on whole-blood analyte detection for near-patient testing.
Ravi Chana
Ravi is Executive Director for Diagnostics at ABHI, bringing over 30 years of experience in life sciences, diagnostics, and business development. Previously Head of Business Development for Roche Diagnostics UK, he led value-based healthcare initiatives and collaborated with global teams and MedTech innovators to accelerate technology adoption. His expertise spans health economics, NICE submissions, and navigating NHS adoption challenges. Ravi has also held roles as a sector specialist for the Department for International Trade and in business development for NIHR, giving him a comprehensive understanding of the commercial and regulatory landscape for medical diagnostics.